Brought to you by 
Glaxo pays £61mm for remaining shares of its partner Cellzome
21 Jun 2022
Executive Summary
GlaxoSmithKline PLC is acquiring the 80.02% remaining outstanding shares of its long-time partner, privately held chemoproteomics company Cellzome AG, that it didn’t already own for £61mm ($99mm). Cellzome will be integrated with GSK’s R&D organization. Concurrent with the acquisition, certain Cellzome assets and activities that GSK will no longer pursue will be spun off into a new start-up.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Partial Acquisition
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Glaxo pays £61mm for remaining shares of its partner Cellzome
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice